Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971612 | 0.76 | BCHE (0.51) | — | |
| SCHEMBL19971611 | 0.76 | BCHE (0.51) | — | |
| SCHEMBL18517359 | 0.76 | BCHE (0.51) | — | |
| SCHEMBL20844347 | 0.76 | KMT2A (0.54) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL19986248 | 0.74 | KMT2A (0.62) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL19971697 | 0.73 | MEN1 (0.54) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL18517357 | 0.73 | MEN1 (0.54) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL19971698 | 0.73 | MEN1 (0.54) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL16775234 | 0.73 | KMT2A (0.70) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL16759895 | 0.73 | KMT2A (0.70) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | MEN1 338/4885KMT2A 1929/4885ALDH1A1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.